MarketBeat
27 Oct 2026, 04:02 UTC · 2h ago
Impact · against what's priced in
ArriVent BioPharma sees a positive catalyst from strong Phase I efficacy (44.8% ORR) and a manageable safety profile for ARR-217 in colorectal cancer. The news establishes a clear catalyst timeline for 2027, including Phase Ib data in H1 and a target Phase III start by year-end.
No priced-in read yet
What the story claims
5 claims · scored −1 bearish … +1 bullish · 5 new · 0 priced in
ARR-217 achieved a 44.8% objective response rate and a 93.1% disease-control rate at the 6 mg/kg dose in metastatic colorectal cancer patients.
Newpresented during a virtual webinar following an ESMO late-breaking oral
So whatThese results support the company's target of starting a Phase III trial by end-2027.
More positive than 99% of claims this week
Continue reading
5 related stories
The 44.8% objective response rate and 93.1% disease-control rate at the 6 mg/kg dose provide strong early evidence of efficacy in heavily pretreated metastatic colorectal cancer patients. Additionally, the manageable safety profile (2% Grade 3+ diarrhea) and the concrete roadmap toward a Phase III trial by end-2027 create a positive valuation catalyst.
Read from the article alone
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
The company expects to report additional Phase Ib monotherapy data, including durability and progression-free survival, in the first half of 2027.
Newpresented during a virtual webinar following an ESMO late-breaking oral
So whatThe next major catalyst for AVBP stock is now set for H1 2027.
More positive than 78% of claims this week
At the 6 mg/kg dose, the company reported a 2% rate of Grade 3 or higher diarrhea and no treatment discontinuations due to adverse events.
Newpresented during a virtual webinar following an ESMO late-breaking oral
More positive than 64% of claims this week
ArriVent recently enrolled the first patient in a Phase I study of ARR-002, a dual-targeting ADC directed at NaPi2b and MUC16.
Newpresented during a virtual webinar following an ESMO late-breaking oral
More positive than 51% of claims this week
The company plans to provide a program update on the Phase III ALPACCA trial of firmonertinib in the first quarter of 2027.
Newpresented during a virtual webinar following an ESMO late-breaking oral
So whatInvestors have a concrete window for the next lung cancer data read-out in Q1 2027.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
Positive Phase I data for ARR-217 showing strong objective response rates and a manageable safety profile.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
14h ago
—
AVBP hasn't traded since this ran. Last close $15.36 (Oct 26); the reaction starts at the next open.
AVBP chart →
